medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-10-103-106medsovet-2540Research ArticleПоддерживающая терапия в онкологииSupportive care in oncologyВозможности применения бемипарина в профилактике и лечении тромбозов в онкологииThe prospects for using bemiparin in prophylaxis and treatment of thromboses in oncologyСомоноваО. B.SomonovaO. V.

Доктор медицинских наук 

Москва

MD

Moscow

ЕлизароваА. Л.ElizarovaA. L.

Кандидат биологических наук 

Москва

PhD in Biology 

Moscow

НестероваЮ. А.NesterovaYu. A.БорисенкоН. Н.BorisenkoN. N.КорнюшенкоУ. А.KornyushenkoU. A.ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of RussiaRussian Federation201818072018010103106Copyright © Сомонова О.B., Елизарова А.Л., Нестерова Ю.А., Борисенко Н.Н., Корнюшенко У.А., 20182018Сомонова О.B., Елизарова А.Л., Нестерова Ю.А., Борисенко Н.Н., Корнюшенко У.А.Somonova O.V., Elizarova A.L., Nesterova Y.A., Borisenko N.N., Kornyushenko U.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2540

Онкологические больные подвержены высокому риску тромботических осложнений, которые ухудшают исходы противоопухолевого лечения и занимают одно из лидирующих мест среди причин смерти. Низкомолекулярные гепарины являются основными препаратами в профилактике и лечении тромботических осложнений у онкологических больных. Цибор (бемипарин) – низкомолекулярный гепарин второго поколения, имеет наименьшую молекулярную массу (3600 Дальтон), увеличенный до 5,3 ч период полужизни и самую высокую активность в отношении Xа-фактора (8:1). В клинических исследованиях бемипарин продемонстрировал высокую эффективность и безопасность в профилактике и лечении тромбоэмболических осложнений.

Oncological patients have a high risk of thrombotic complications, which worsen the outcomes of antitumor treatment and is one of the leading causes of death. Low molecular weight heparins are the main drugs for the prevention and treatment of thrombotic complications in cancer patients. Zibor (bemiparin) is a second-generation low-molecular-weight heparin (LMWH) that has the lowest molecular weight (3600 Dalton), a half-life increased to 5.3 hours and the highest anti-Factor Xa activity ratio (8:1). In clinical trials, bemiparin has demonstrated high efficacy and safety for prophylaxis and treatment of thromboembolic complications.

онкологические больныетромботические осложнениянизкомолекулярные гепариныЦибор (бемипарин натрия)oncological patientsthrombotic complicationslow molecular weight heparinsZibor (sodium beimiparin).ReferencesAgnelli G, Verso M. Management of venous thromboembolism in patients with cancer. Journal of thrombosis and Haemostasis, 2011, 9(Suppl 1): 316-324.Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. Journal of thrombosis and Haemostasis, 2011, 9(Suppl 1): 316-324.Barsam SJ, Patel R, Arya. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. British J of Haematology, 2013, 161(Iss. 6): 764-777.Barsam SJ, Patel R, Arya. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. British J of Haematology, 2013, 161(Iss. 6): 764-777.Robin P, Carrier M. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research, 2018, 164(Suppl.1): S7-S11.Robin P, Carrier M. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research, 2018, 164(Suppl.1): S7-S11.Magnus N, D’Asti E, Meehan B et al. Oncogenes and the coagulation system – forses that modulate dormant and aggressive states in cancer. Thrombosis Research, 2014, 133(Suppl. 2): S1-S9.Magnus N, D’Asti E, Meehan B et al. Oncogenes and the coagulation system – forses that modulate dormant and aggressive states in cancer. Thrombosis Research, 2014, 133(Suppl. 2): S1-S9.Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thrombosis Research, 2018, 164(Suppl.1): S54-S61.Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thrombosis Research, 2018, 164(Suppl.1): S54-S61.Cedervall J, Hamidi A, Olsson A-K. Platelets, NETs and cancer. Thrombosis Research, 2018, 164(Suppl.1): S48-S52.Cedervall J, Hamidi A, Olsson A-K. Platelets, NETs and cancer. Thrombosis Research, 2018, 164(Suppl.1): S48-S52.Ten CH, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb, 2007, 36: 122-130.Ten CH, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb, 2007, 36: 122-130.Agnelii G, Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thrombosis Research, 2010, 125(Suppl.2): S17-S20.Agnelii G, Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thrombosis Research, 2010, 125(Suppl.2): S17-S20.Weitz JI. Potential of new anticoagulsnts in patients with cancer. Thrombosis Research, 2010, 125(Suppl 2): S30-S35.Weitz JI. Potential of new anticoagulsnts in patients with cancer. Thrombosis Research, 2010, 125(Suppl 2): S30-S35.Levine MN, Lee AY, Kakkar AK. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting, 2005: 748-577.Levine MN, Lee AY, Kakkar AK. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting, 2005: 748-577.Lee AY. The roles of anticoagulants in patients with cancer. Thromb Res, 2010, 125(Suppl. 2): S8-S11.Lee AY. The roles of anticoagulants in patients with cancer. Thromb Res, 2010, 125(Suppl. 2): S8-S11.Cohen AT, Nandini B, Wills JO et al. VTE prophylaxis for the medical patients: where do we stand? A focus on cancer patients. Thromb. Res, 2010, 125(Suppl 2): S21-S29.Cohen AT, Nandini B, Wills JO et al. VTE prophylaxis for the medical patients: where do we stand? A focus on cancer patients. Thromb. Res, 2010, 125(Suppl 2): S21-S29.Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical Practice Guideline Update 2014. J Clin Oncol, 2015, 33: 654–656.Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical Practice Guideline Update 2014. J Clin Oncol, 2015, 33: 654–656.Kuderer NM, Lyman GH. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res, 2014, 133(Suppl. 2): S122-S127.Kuderer NM, Lyman GH. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res, 2014, 133(Suppl. 2): S122-S127.Kearon C, Akl EA, Ornelas J et al. Antithrombotic therapy for VTE disease. Chest, 2016, 149(2): 315-352.Kearon C, Akl EA, Ornelas J et al. Antithrombotic therapy for VTE disease. Chest, 2016, 149(2): 315-352.Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest, 2001, 119(Suppl. 1): 64S-94S.Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest, 2001, 119(Suppl. 1): 64S-94S.Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to Anticoagulant therapy: Heparin. A Statement for healthcare Professionals from the American Heart Association. Curculation, 2001: 2994-3018.Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to Anticoagulant therapy: Heparin. A Statement for healthcare Professionals from the American Heart Association. Curculation, 2001: 2994-3018.Mismetti P, Laporte S, Darmon JY et al. Metaanalysis of low-molecular-weight heparin in the prevention pf venous thromboembolism in general surgery. Br J Surg, 2001, 88: 913-930.Mismetti P, Laporte S, Darmon JY et al. Metaanalysis of low-molecular-weight heparin in the prevention pf venous thromboembolism in general surgery. Br J Surg, 2001, 88: 913-930.Martinez-Gonzalez J, Vila L, Rodriguez C. Bemiparin: second-generation, low-molecularweight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev Cardiovasc. Ther, 2008 Jul, 6(6): 793-802.Martinez-Gonzalez J, Vila L, Rodriguez C. Bemiparin: second-generation, low-molecularweight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev Cardiovasc. Ther, 2008 Jul, 6(6): 793-802.Morita S, Gebska MA, Kakkar AK, Scully MF. High affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood, 2002, 99: 2221-7.Morita S, Gebska MA, Kakkar AK, Scully MF. High affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood, 2002, 99: 2221-7.Balibrea JL, Altimiras J, Larruzea I et al. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int J Surg, 2007 Apr, 5(2): 114-119.Balibrea JL, Altimiras J, Larruzea I et al. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int J Surg, 2007 Apr, 5(2): 114-119.Величко Э.В., Хачукаева А.С., Хабадзе З.С. и др. Место бемипарина в современной клинической практике. Трудный пациент, 2017, 15(10-11): 11-14.Velichko EV, Trudny Patient, 2017, 15 (10-11): 11-14.Kakkar W, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomizied trial of a new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb Haemost, 2000, 83: 523-529.Kakkar W, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomizied trial of a new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb Haemost, 2000, 83: 523-529.Navarro-Quilis A, Castellet E, Rocha E,PazJimenez J, Planes A. Efficasy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty. A randomized doubleblind clinical trial. Thromb Haemost, 2003, 1: 425-432.Navarro-Quilis A, Castellet E, Rocha E,PazJimenez J, Planes A. Efficasy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty. A randomized doubleblind clinical trial. Thromb Haemost, 2003, 1: 425-432.Rodriguez-Manas L, Gomez-Huelgas R, VeigaFernandez F, Ruiz GM, Gonzalez JM. Thromboprophylaxis with the low -molecular – weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study. Clin Drug Investig, 2010, 30(5): 337-45.Rodriguez-Manas L, Gomez-Huelgas R, VeigaFernandez F, Ruiz GM, Gonzalez JM. Thromboprophylaxis with the low -molecular – weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study. Clin Drug Investig, 2010, 30(5): 337-45.Monreal BM, Vignoli A, Lecumberri VR et al. Bemiparin in oncology. Drugs, 2010, Dec 14, 70(Suppl 2): 35-42.Monreal BM, Vignoli A, Lecumberri VR et al. Bemiparin in oncology. Drugs, 2010, Dec 14, 70(Suppl 2): 35-42.ABEL trial: A phase II randomized trial adding bemiparin to chemo-radiotherapy in limitedstage small cell lung cancer (SCLC) – Final results, 2912 ASCO Annual Meeting. Abstr.7095. Cit. In J Clin Oncol, 2012: 30.ABEL trial: A phase II randomized trial adding bemiparin to chemo-radiotherapy in limitedstage small cell lung cancer (SCLC) – Final results, 2912 ASCO Annual Meeting. Abstr.7095. Cit. In J Clin Oncol, 2012: 30.

The authors declare that there are no conflicts of interest present.